Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2024-08-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
2024年半年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024 Half-Year Special Report on the Deposit and Use of Raised Funds" by Tianjin Ruipu Biotechnology Co., Ltd. It details the management, storage, and usage of funds raised through a specific stock issuance approved by the China Securities Regulatory Commission in 2021. The report includes detailed financial figures on the amount raised, usage during the reporting period, balances, and investment projects funded by these raised funds. It also references compliance with regulatory guidelines on raised funds management and includes a detailed table of fund usage and project progress. The document is a specialized report focused on the use of capital raised by the company, not a general financial report or earnings release. This type of document aligns with a Capital/Financing Update (CAP) category, as it provides updates on fundraising and the use of those funds. The document length (8407 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2024-08-23 Chinese
关于使用闲置自有资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the use of idle funds to purchase financial products. It details the investment purpose, types, amounts, risk analysis, risk control measures, and approvals by the board and supervisory committee. The document references compliance with Shenzhen Stock Exchange rules and company articles but does not contain financial statements or detailed financial performance data. It is a disclosure about financing activities related to the company's capital management rather than a full financial report or earnings release. The document length is 2863 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-08-23 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024 半年度报告摘要" which translates to "2024 Half-Year Report Summary." It contains financial data and key accounting figures for the half-year period, including revenue, net profit, assets, shareholder information, and other financial indicators. The document is a summary of the half-year report, which is a type of interim or quarterly report. The length is under 5,000 characters but it contains substantive financial data and analysis, not just an announcement or a link to a report. Therefore, it should be classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-23 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 16th meeting of the 5th Board of Directors of Tianjin Ruipu Biotechnology Co., Ltd. It includes details about the meeting date, attendance, and voting results on several agenda items such as approval of the 2024 semi-annual report, a special report on the use of raised funds, and proposals related to the use of idle funds for financial products and cash management. The document does not contain the actual semi-annual report or financial statements but refers to where these reports can be found online. The document is primarily a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1907 characters), and it is not a full financial report or earnings release but an announcement of board decisions.
2024-08-23 Chinese
2024年半年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is very short (324 characters) and is titled as a "2024年半年度报告披露提示性公告" which translates to "2024 Semi-Annual Report Disclosure Reminder Announcement." It states that the company's 2024 semi-annual report and summary have been disclosed on official websites and advises investors to review them. There is no actual financial data or detailed report content included, only a notice about the report's availability. According to the MENU VS MEAL RULE, this is an announcement about the report publication, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2024-08-23 Chinese
中国银河证券股份有限公司关于天津瑞普生物技术股份有限公司使用闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from China Galaxy Securities regarding Tianjin Ruipu Biotechnology Co., Ltd.'s use of idle raised funds for cash management. It includes information about the board meeting approving the use of idle raised funds, the amount and purpose of the raised funds, investment projects, risk control measures, and the compliance with regulatory requirements. The document is a formal verification or audit opinion related to the use of raised funds, not the actual financial report or annual report itself. It does not contain comprehensive financial statements or management discussion and analysis but rather a specific audit/verification opinion on a particular financial activity. The document length is under 5,000 characters, but it is substantive and not merely an announcement of a report. Given the nature of the content, it fits best under Audit Report / Information (AR), which covers standalone audit reports and verification opinions related to financial matters excluding full annual reports. Q3 2024
2024-08-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.